New pill could stop liver scarring in MASH patients
NCT ID NCT07581951
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether the drug HSK31679 can safely improve liver health in 400 adults with MASH, a serious fatty liver disease. Participants will take either the drug or a placebo daily for about a year. The main goals are to see if the drug can reverse liver inflammation and scarring without making the disease worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK31679 (a tablet drug)
- What this could lead to
- If it works, this could lead to a new treatment that reverses liver inflammation and scarring in people with MASH, potentially preventing liver failure.
- What could go wrong
- This is a large Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results won't be available for several years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a once-daily pill help children with fatty liver disease?
- Could a common sugar fuel liver damage?
- Can eating only during an 8-10 hour window help liver cancer patients?
- Could a quick liver scan replace needle biopsies for MASH in diabetics?
- New registry tracks rezdiffra safety for moms and babies
- Exercise may fight fatty liver in seniors, new study hopes to prove